Oral Micronized Progesterone Geriatric (65+) Dosing

Why Geriatric Dosing Differs From Standard Adult Dosing

Older adults metabolize oral micronized progesterone differently than younger postmenopausal women. Starting at the standard 200 mg cyclic dose in a 70-year-old carries a meaningfully higher risk of next-day sedation, confusion, and falls than the same dose in a 52-year-old.

Pharmacokinetic Changes After Age 65

OMP is metabolized primarily in the liver via CYP3A4 and CYP2C19, and its active metabolites (allopregnanolone, 5-alpha-dihydroprogesterone) are cleared renally. Hepatic blood flow decreases by roughly 40% between ages 25 and 75, reducing first-pass extraction and raising systemic exposure. Glomerular filtration rate (GFR) declines at approximately 1 mL/min per year after age 40, meaning a 70-year-old woman with a serum creatinine that appears normal may have an eGFR below 60 mL/min/1.73m². That slower renal clearance allows neuroactive metabolites to accumulate.

A pharmacokinetic analysis published in the journal Steroids found that peak plasma concentrations of allopregnanolone, the GABA-A receptor-positive modulator derived from progesterone, were significantly higher in older women given the same 200 mg oral dose compared with younger controls (PMID 7878465). Higher allopregnanolone levels correlate directly with sedation scores on the Digit Symbol Substitution Test, a standard psychomotor measure used in CNS drug trials.

Volume of Distribution and Protein Binding

Progesterone is approximately 96% protein-bound, primarily to albumin and corticosteroid-binding globulin. Serum albumin drops by roughly 3 to 5 g/L between the third and eighth decades of life, increasing the free fraction of progesterone available to cross the blood-brain barrier. This amplifies sedative and anxiolytic effects even at doses that were well-tolerated years earlier in the same patient.

What This Means Clinically

A woman who tolerated 200 mg cyclic OMP at age 56 may notice pronounced dizziness or morning grogginess at age 67 on the same regimen. Dose reduction to 100 mg continuous is often the practical fix, and it preserves full endometrial protection in women with an intact uterus receiving systemic estrogen therapy.

Evidence Base: PEPI Trial and Endometrial Protection Data

The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial, published in JAMA in 1995 (N=875, multicenter, 3-year randomized controlled trial), remains the foundational study comparing OMP with medroxyprogesterone acetate (MPA) for endometrial protection in postmenopausal women (PMID 7837245).

PEPI Trial Key Findings

The trial assigned women to one of five arms: placebo, conjugated equine estrogen (CEE) alone, CEE plus MPA (continuous), CEE plus MPA (cyclic), or CEE plus micronized progesterone 200 mg cyclic. Endometrial hyperplasia rates at 3 years were below 1% in all active progestogen arms. The OMP cyclic arm also produced a statistically superior HDL-cholesterol profile compared with MPA arms. The PEPI authors wrote: "Micronized progesterone did not attenuate the estrogen-associated increase in HDL-C, whereas MPA did."

That lipid advantage matters more, not less, in women over 65, whose 10-year cardiovascular risk is typically higher than in newly menopausal women. Choosing OMP over MPA in an older woman with borderline HDL may carry a cardioprotective signal, though the PEPI trial was not powered to detect cardiovascular events directly.

Applicability to the 65+ Population

PEPI enrolled women aged 45 to 64, so direct extrapolation to adults over 65 requires clinical judgment. The NAMS 2022 Hormone Therapy Position Statement notes that "the decision to continue, change, or stop hormone therapy in women over 60 should be individualized, weighing benefits against risks including venous thromboembolism, stroke, and breast cancer" (NAMS 2022).

The endometrial protection data from PEPI is still considered applicable across postmenopausal age groups because the mechanism (progestogen-induced secretory transformation of the endometrium) does not diminish with age. What changes is the tolerance profile, not the organ-level efficacy.

Recommended Dosing Regimens in Adults 65 and Older

No FDA-approved labeling for Prometrium specifies a geriatric dose adjustment. The Prometrium prescribing information states only that "the pharmacokinetics of Prometrium Capsules have not been assessed in women over age 65." That absence of data is itself clinically meaningful.

Continuous Regimen (Preferred in Geriatric Patients)

100 mg orally at bedtime, taken every night without cycling. This is the regimen most commonly used in clinical practice for older women receiving systemic estrogen because it avoids the monthly withdrawal bleed that cyclic regimens can produce in some patients, and it uses a lower nightly dose that reduces peak allopregnanolone exposure.

Taking OMP at bedtime is not optional in this age group. It is the single most important administration instruction. The sedative effect, which peaks at approximately 2 to 4 hours post-dose, becomes a therapeutic advantage when it coincides with sleep onset, and a fall-risk hazard when it does not.

Cyclic Regimen (Use With Caution Over 65)

200 mg nightly for 12 to 14 consecutive days per calendar month. This mirrors the PEPI trial protocol and is supported for endometrial protection. In women over 65, the 200 mg dose on cyclic days should still be taken at bedtime. Clinicians should document a falls-risk assessment before initiating the 200 mg dose, especially if the patient also takes a benzodiazepine, Z-drug, or gabapentinoid.

Ultra-Low Dose Continuous (Off-Label, Emerging Evidence)

Some clinicians use 50 mg nightly for women over 70 who are receiving low-dose transdermal estradiol (0.025 mg/day patch) and who have demonstrated sensitivity to the 100 mg dose. This is off-label; no randomized trial has confirmed endometrial protection at 50 mg. If this approach is chosen, endometrial surveillance with transvaginal ultrasound every 12 months is reasonable, with biopsy triggered by an endometrial stripe above 4 mm in a postmenopausal woman.

Fall and Fracture Risk: The Central Safety Issue

Falls are the leading cause of injury death in adults over 65. The CDC reports that approximately 36 million falls occur in U.S. Adults 65 and older each year, resulting in more than 32,000 deaths (CDC Falls Data). Any medication that increases sedation or impairs balance belongs on the fall-risk radar.

How OMP Affects Balance and Cognition

Allopregnanolone, the primary neuroactive metabolite of oral progesterone, is a potent positive allosteric modulator of GABA-A receptors. Its mechanism of action is pharmacologically similar to that of benzodiazepines, though it acts at a distinct binding site. In a crossover pharmacodynamic study (N=40, premenopausal and postmenopausal women), 300 mg OMP produced measurable impairment on saccadic eye velocity and body sway testing at 2 and 4 hours post-dose compared with placebo (PMID 10565671). The effect was greater in older participants.

For reference, 300 mg is higher than the standard geriatric dose recommended here. At 100 mg, psychomotor impairment is measurable but substantially attenuated. Still, even mild impairment compounds existing age-related gait instability.

Practical Mitigation Strategies

A targeted approach works better than a blanket warning. Specific steps include:

• Confirm the patient takes OMP at bedtime and stays seated or supine for at least 30 minutes after ingestion.
• Review the full medication list for additive CNS depressants: opioids, benzodiazepines, muscle relaxants, first-generation antihistamines, and tricyclic antidepressants.
• Use the STEADI (Stopping Elderly Accidents, Deaths, and Injuries) algorithm from the CDC to stratify baseline fall risk before starting OMP (CDC STEADI).
• If the patient scores high on STEADI at baseline, the 100 mg continuous regimen is preferred over 200 mg cyclic.

Drug-Drug Interactions in Geriatric Patients

Polypharmacy is nearly universal in adults over 65. The average Medicare beneficiary fills prescriptions for 4 to 5 chronic medications. OMP's interaction profile is manageable but warrants systematic review.

CYP3A4 Interactions

OMP is both a substrate and a weak inhibitor of CYP3A4. Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) accelerate OMP metabolism and may reduce endometrial protection. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit juice in large amounts) may increase OMP exposure and amplify sedation. In an older patient taking carbamazepine for trigeminal neuralgia, switching to an alternative progestogen or increasing endometrial surveillance is a reasonable clinical step.

Additive CNS Depression

The combination of OMP with gabapentin or pregabalin deserves special attention. Both gabapentinoids are prescribed frequently in older women for neuropathic pain and are also independently associated with fall risk. Adding OMP to either drug may produce additive psychomotor impairment that exceeds the effect of either agent alone. No published interaction study specifically addresses this combination, but the mechanistic overlap with GABA-A modulation is a plausible shared pathway.

Anticoagulants

Progesterone has no clinically established direct interaction with warfarin, but it may have weak pro-thrombotic effects via changes in coagulation factor synthesis. Women over 65 on warfarin should have INR monitored within 4 to 6 weeks of starting or stopping OMP, as the interaction is unpredictable at the individual level.

Renal Function and Dose Considerations

No formal renal dose adjustment guidelines exist for OMP. The prescribing information does not stratify dosing by GFR. Clinical practice relies on indirect inference from pharmacokinetic principles.

GFR Below 30 mL/min

Women with an eGFR below 30 mL/min/1.73m² may accumulate progesterone metabolites more than those with normal renal function. The 100 mg continuous bedtime dose is the rational starting point. Monthly clinical assessment for sedation, dizziness, and confusion during the first 3 months is reasonable. If sedation persists despite bedtime dosing, a trial at 50 mg nightly (with enhanced endometrial surveillance) may be considered in shared-decision discussion with the patient.

Hemodialysis

No published pharmacokinetic data exist for OMP in women on hemodialysis. The lipophilicity of progesterone suggests that hemodialysis does not substantially remove it. Starting at 100 mg nightly with close monitoring is the pragmatic approach. Specialty nephrology-gynecology consultation is appropriate before initiating OMP in a dialysis-dependent patient.

When to Deprescribe: Stopping OMP in Older Women

Deprescribing is an active clinical decision, not a default. The primary indication for OMP in postmenopausal women is endometrial protection in those with an intact uterus who are receiving systemic estrogen therapy. If estrogen therapy stops, OMP stops with it.

The Post-Hysterectomy Patient

Women who have had a hysterectomy do not have an endometrium to protect. OMP has no FDA-approved indication in this group. If a post-hysterectomy woman over 65 has been prescribed OMP for sleep or mood support (off-label uses), that indication should be explicitly documented and reviewed annually. The sedation risk profile does not diminish over time.

The 5-Year and 10-Year Reassessment

The NAMS 2022 Position Statement recommends reassessing hormone therapy annually. In a 70-year-old who started HRT at 65, the cumulative duration question is active. Observational data from the Million Women Study (N=1,084,110) and the WHI Extension Study suggest that prolonged combined estrogen-progestogen therapy is associated with a small incremental increase in breast cancer risk compared with estrogen alone (PMID 12860938). Reducing OMP to the lowest effective dose or transitioning to vaginal progesterone (if local endometrial protection is the only goal and systemic estrogen is low-dose transdermal) may reduce that incremental risk, though this strategy remains investigational.

Tapering Versus Abrupt Discontinuation

No withdrawal syndrome comparable to benzodiazepine discontinuation has been documented with OMP. Abrupt cessation is generally safe. Some women report transient sleep disruption in the 1 to 2 weeks after stopping, which is consistent with the loss of allopregnanolone's GABAergic support. Tapering from 100 mg to 50 mg for 4 weeks before stopping is a low-risk option if the patient reports sleep dependence, though this 50 mg dose is off-label.

Monitoring Parameters for Geriatric Patients on OMP

Structured monitoring reduces preventable harm without creating excessive clinic burden. The table below summarizes what to check and when.

| Parameter | Timing | Threshold for Action | |---|---|---| | Endometrial stripe (TVUS) | Every 12 months (continuous regimen) | >4 mm: biopsy | | Falls assessment (STEADI) | Baseline, then annually | High risk: dose review | | Sedation/dizziness screen | 4 weeks post-start, then annually | Persistent: consider dose reduction | | eGFR | Annually | <30: increase monitoring frequency | | Medication reconciliation | Each visit | New CYP3A4 inhibitors or CNS depressants: interaction review | | Breast cancer risk discussion | Annually after 5 years of combined HRT | Elevated 10-year risk: shared deprescribing discussion |

Formulation Notes Specific to Older Adults

Capsule Swallowing Difficulty

Some women over 65 have dysphagia. Prometrium is a 100 mg or 200 mg soft gelatin capsule. The manufacturer does not recommend crushing or opening the capsule because the peanut oil base is integral to bioavailability. For women with swallowing difficulty, compounded vaginal progesterone in a suppository form is an alternative, though compounded formulations lack the regulatory oversight of FDA-approved Prometrium.

Peanut Oil Content

Prometrium capsules contain peanut oil. This is not a theoretical concern: anaphylaxis has been reported. Every prescribing encounter for a geriatric patient should include a verbal or documented allergy confirmation. If peanut allergy is present, a compounded progesterone product in a different oil base (sesame, sunflower) or a different progestogen entirely should be used.

Food Timing

Taking OMP with a high-fat meal increases peak plasma concentration (Cmax) roughly 2-fold and area-under-the-curve (AUC) by approximately 45%, based on pharmacokinetic data in the FDA label. In geriatric patients already at higher baseline exposure, taking OMP on a full stomach versus an empty stomach produces a clinically meaningful difference in sedation intensity. The recommendation to take it at bedtime applies regardless of food; however, clinicians should ask whether the patient takes it with a late-night snack, since that food-effect amplification is an underappreciated source of variable tolerance.

Shared Decision-Making With Older Patients

Women over 65 bring lived experience to medication decisions. Many have taken HRT for a decade or more. Others are initiating it for the first time to manage persistent vasomotor symptoms, which affect approximately 42% of women at age 60 and 17% at age 70, based on the Study of Women's Health Across the Nation (SWAN) longitudinal cohort (PMID 16291985).

The conversation about OMP dose in an older woman should cover four specific points:

1. Why the dose is lower than what a younger woman takes (pharmacokinetic explanation, brief).
2. The bedtime-only rule and what to do if she wakes at night and feels unsteady.
3. The annual review commitment, so she understands this is not a set-it-and-forget-it prescription.
4. The peanut allergy question, asked explicitly every time at initiation.

These four points take under 3 minutes to cover and meaningfully reduce the most common preventable adverse outcomes in this age group.